Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updates on the understanding and management of thyroid eye disease.
Men CJ, Kossler AL, Wester ST. Men CJ, et al. Among authors: kossler al. Ther Adv Ophthalmol. 2021 Jun 30;13:25158414211027760. doi: 10.1177/25158414211027760. eCollection 2021 Jan-Dec. Ther Adv Ophthalmol. 2021. PMID: 34263138 Free PMC article. Review.
Thyroid Eye Disease: Navigating the New Treatment Landscape.
Dosiou C, Kossler AL. Dosiou C, et al. Among authors: kossler al. J Endocr Soc. 2021 Mar 17;5(5):bvab034. doi: 10.1210/jendso/bvab034. eCollection 2021 May 1. J Endocr Soc. 2021. PMID: 33948524 Free PMC article.
Teprotumumab for the treatment of chronic thyroid eye disease.
Ugradar S, Kang J, Kossler AL, Zimmerman E, Braun J, Harrison AR, Bose S, Cockerham K, Douglas RS. Ugradar S, et al. Among authors: kossler al. Eye (Lond). 2022 Aug;36(8):1553-1559. doi: 10.1038/s41433-021-01593-z. Epub 2021 Jul 9. Eye (Lond). 2022. PMID: 34244669 Free PMC article.
Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN, Liu J, Hoffman AR, Swanson A, Alyono J, Lee JY, Dosiou C, Kossler AL. Sears CM, et al. Among authors: kossler al. Am J Ophthalmol. 2022 Aug;240:1-13. doi: 10.1016/j.ajo.2022.02.015. Epub 2022 Feb 25. Am J Ophthalmol. 2022. PMID: 35227694 Free PMC article.
Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
Douglas RS, Kossler AL, Abrams J, Briceño CA, Gay D, Harrison A, Lee M, Nguyen J, Joseph SS, Schlachter D, Tan J, Lynch J, Oliver L, Perry R, Ugradar S. Douglas RS, et al. Among authors: kossler al. J Neuroophthalmol. 2022 Sep 1;42(3):334-339. doi: 10.1097/WNO.0000000000001560. Epub 2022 Mar 24. J Neuroophthalmol. 2022. PMID: 35421877 Free PMC article.
Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
Ho TC, Maamari RN, Kossler AL, Sears CM, Freitag SK, Reshef ER, Shinder R, Rootman DB, Diniz SB, Kahana A, Schlachter D, Do TH, Kally P, Turner S, Mokhtarzadeh A, Harrison AR, Hwang CJ, Kim HJ, Avila SA, Thomas DA, Magazin M, Wester ST, Lee WW, Clauss KD, Holds JB, Sniegowski M, Compton CJ, Briggs C, Malik AI, Lucarelli MJ, Burkat CN, Patel LG, Couch SM. Ho TC, et al. Among authors: kossler al. Ophthalmic Plast Reconstr Surg. 2023 Mar-Apr 01;39(2):150-155. doi: 10.1097/IOP.0000000000002267. Epub 2022 Sep 9. Ophthalmic Plast Reconstr Surg. 2023. PMID: 36095848 Free PMC article.
82 results